Bank of Nova Scotia
BIO icon

Bank of Nova Scotia’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bank of Nova Scotia’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-861
Closed -$288K – 1056
2024
Q3 		$288K Sell
861
-1,239
-59% -$394K ﹤0.01% 919
2024
Q2 		$574K Sell
2,100
-562
-21% -$163K ﹤0.01% 834
2024
Q1 		$921K Buy
2,662
+28
+1% +$9.21K ﹤0.01% 786
2023
Q4 		$850K Buy
2,634
+655
+33% +$205K ﹤0.01% 794
2023
Q3 		$709K Buy
1,979
+221
+13% +$85.3K ﹤0.01% 758
2023
Q2 		$666K Buy
1,758
+250
+17% +$102K ﹤0.01% 735
2023
Q1 		$722K Sell
1,508
-290
-16% -$136K ﹤0.01% 775
2022
Q4 		$756K Sell
1,798
-6
-0.3% -$2.42K ﹤0.01% 855
2022
Q3 		$753K Sell
1,804
-2
-0.1% -$997 ﹤0.01% 863
2022
Q2 		$893K Sell
1,806
-20,198
-92% -$10.5M ﹤0.01% 874
2022
Q1 		$12.4M Sell
22,004
-3,436
-14% -$2.07M 0.02% 407
2021
Q4 		$19.2M Buy
25,440
+14,785
+139% +$11.1M 0.03% 392
2021
Q3 		$7.95M Buy
10,655
+7,312
+219% +$5.48M 0.01% 526
2021
Q2 		$2.15M Sell
3,343
-1,554
-32% -$946K ﹤0.01% 803
2021
Q1 		$2.8M Buy
4,897
+210
+4% +$124K 0.01% 717
2020
Q4 		$2.73M Buy
4,687
+800
+21% +$456K 0.01% 636
2020
Q3 		$2M Buy
+3,887
New +$1.97M 0.01% 641
2020
Q2 		– Sell
-55,668
Closed -$19.5M – 947
2020
Q1 		$19.5M Buy
55,668
+35,121
+171% +$12.9M 0.07% 219
2019
Q4 		$7.6M Sell
20,547
-8,599
-30% -$3.03M 0.02% 433
2019
Q3 		$9.7M Buy
+29,146
New +$9.51M 0.03% 374
2018
Q3 		– Sell
-6,900
Closed -$1.99M – 868
2018
Q2 		$1.99M Buy
+6,900
New +$1.91M 0.01% 506
2016
Q1 		– Sell
-75,000
Closed -$10.4M – 709
2015
Q4 		$10.4M Buy
+75,000
New +$10.4M 0.05% 177
2015
Q3 		– Sell
-150,000
Closed -$22.6M – 670
2015
Q2 		$22.6M Buy
+150,000
New +$21.5M 0.11% 104

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Bank of Nova Scotia's BIO Position: Q4 2024 in Review

Bank of Nova Scotia sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 861 shares — an estimated $288K sold.

Bank of Nova Scotia first reported a position in BIO in Q2 2015 and held it in 23 quarters. The position peaked at $22.6M in Q2 2015. 457 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

  • Bank of Nova Scotia reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
  • Bank of Nova Scotia sold 861 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $288K.
  • Bank of Nova Scotia first reported a position in Bio-Rad Laboratories Class A in Q2 2015 and held it in 23 quarters.
  • Bank of Nova Scotia's Bio-Rad Laboratories Class A position peaked at $22.6M in Q2 2015.
  • 457 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Bank of Nova Scotia's 13F filing for Q4 2024, filed 13 Feb 2025.